<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01171625</url>
  </required_header>
  <id_info>
    <org_study_id>2007-08</org_study_id>
    <nct_id>NCT01171625</nct_id>
  </id_info>
  <brief_title>Carpentier-Edwards PERIMOUNT Magna Ease Pericardial Bioprosthesis, Model 3300TFX</brief_title>
  <official_title>Carpentier-Edwards PERIMOUNT Magna Ease Pericardial Bioprosthesis in the Aortic Position, Model 3300TFX</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Edwards Lifesciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Edwards Lifesciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to demonstrate the long term safety and effectiveness of the
      Carpentier-Edwards PERIMOUNT Magna Ease Valves in patients undergoing aortic valve
      replacement with or without concomitant procedures requiring cardiopulmonary bypass.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, single-arm, multi-center, interventional study to be conducted in the
      US and outside the US (OUS). This study will enroll a minimum of 225 patients implanted with
      the study valve in order to achieve 101 aortic valve replacement subjects each followed for a
      minimum of 8 years. The study will include male and female patients, 18 years or older,
      requiring replacement for a diseased, damaged or malfunctioning natural or prosthetic aortic
      valve. Patients will be followed and assessed after implant annually for a minimum of 8
      years.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Long term safety performance will be evaluated by comparing the linearized yearly rates listed below to the objective performance criteria (OPC) referenced in the Food and Drug Administration (FDA) 1994 Draft Heart Valve Guidance</measure>
    <time_frame>Entire study period (8 yrs post implant)</time_frame>
    <description>a) Thromboembolism, b) All Hemorrhage, c) All Perivalvular Leak, d) Endocarditis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Early rates, late linearized rates, and actuarial rates</measure>
    <time_frame>Entire study period (8 yrs post implant)</time_frame>
    <description>Early rates, late linearized rates, and actuarial rates of: a) Thromboembolism b) Valve Thrombosis, c) All Hemorrhage, d) Major Hemorrhage, e) All Perivalvular leak, f) Major perivalvular leak, g) Endocarditis, h) Hemolysis, i) Structural valve deterioration, j) Non-structural valve dysfunction, k) Reoperation, l) Explant, m) Death, n) Valve Related death</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">225</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Aortic Valve Disorder</condition>
  <condition>Heart Failure</condition>
  <condition>Aortic Valve Stenosis</condition>
  <condition>Aortic Valve Insufficiency</condition>
  <arm_group>
    <arm_group_label>CEP Aortic Bioprothesis, model 3300TFX</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Implantation of CEP Magna Ease Model 3300TFX</intervention_name>
    <description>Heart Valve Surgery</description>
    <arm_group_label>CEP Aortic Bioprothesis, model 3300TFX</arm_group_label>
    <other_name>CEP Magna Ease MOdel 3300TFX</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Primary

          -  Require replacement aortic valve

          -  Signed informed consent

        Exclusion Criteria:

          -  Primary

          -  Active endocarditis (&lt; 3 mths)

          -  Abnormal Ca metabolism

          -  Aneurismal aortic degenerative condition
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mary Edwards</last_name>
    <role>Study Director</role>
    <affiliation>Edwards Lifesciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mercy General Hospital</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95819</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cooper University Hospital</name>
      <address>
        <city>Camden</city>
        <state>New Jersey</state>
        <zip>08103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Morristown Memorial Hospital</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>09762</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Heart &amp; Vascular Institute</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Marks Hospital</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatslinik fur Chirurgie</name>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Paul's Hospital</name>
      <address>
        <city>Vancouver</city>
        <zip>V6Z 1Y6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Liknik fur Herz und BefaBchirurgie Im Deuschen Herzzentrum</name>
      <address>
        <city>Munich</city>
        <state>Lazarettstr</state>
        <zip>36</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik fur Herz-, Thorax-, Transplantations- und Gefabchirurgie</name>
      <address>
        <city>Hannover</city>
        <zip>D-30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Peutra de Hierro</name>
      <address>
        <city>San Martin de Porres 4</city>
        <state>Madrid</state>
        <zip>CP-28035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Papworth Hospital NHS foundation Trust</name>
      <address>
        <city>Papworth Everard</city>
        <state>Cambridge</state>
        <zip>CV23 3RE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Blackpool Victoria Hospital</name>
      <address>
        <city>Blackpool</city>
        <state>Lancashire</state>
        <zip>FY8 8NR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Canada</country>
    <country>Germany</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 26, 2010</study_first_submitted>
  <study_first_submitted_qc>July 27, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 28, 2010</study_first_posted>
  <last_update_submitted>September 22, 2017</last_update_submitted>
  <last_update_submitted_qc>September 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PERIMOUNT, Aortic valve replacement/regurgitation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Aortic Valve Stenosis</mesh_term>
    <mesh_term>Aortic Valve Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

